Stacey Clegg
Cardiovascular Disease · Albuquerque, NMNPI 1396929642
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,363 of the $20,766 with a category attached, or 74.0%. 29 manufacturers reported payments, led by Abiomed at 54.9% of the total. 2025 is the largest year on record at $5,242, 3.6 times the $1,475 reported in 2019. Among cardiovascular disease clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 484 payments — averaging $42.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$11K
- Abbott$3K
- Philips North America LLC$2K
- Cardiovascular Systems Inc.$756
- Boston Scientific$448
- Biosense Webster, Inc.$433
- plus $3K from 23 others
Across 1 payment — averaging $18.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$19
What the payments were for
- Travel & lodging$5,38526%
- Food & beverage$15,36374%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 202 | $11,394 |
| Abbott | 34 | $2,711 |
| Philips North America LLC | 48 | $1,656 |
| Cardiovascular Systems Inc. | 25 | $756 |
| Boston Scientific | 23 | $448 |
| Biosense Webster, Inc. | 14 | $433 |
| E.r. Squibb & Sons, L.L.C. | 12 | $409 |
| Medtronic(2 entities) | 11 | $385 |
| W. L. Gore & Associates, Inc. | 6 | $384 |
| Novartis | 18 | $365 |
| Shockwave Medical, Inc | 29 | $343 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $279 |
| Amgen | 14 | $219 |
| Chiesi USA, Inc. | 6 | $192 |
| Livanova USA, Inc. | 2 | $133 |
| Baxter Healthcare | 3 | $121 |
| Johnson & Johnson | 5 | $112 |
| Cvrx, Inc. | 1 | $92 |
| AstraZeneca | 5 | $83 |
| Pfizer | 3 | $57 |
| Edwards Lifesciences | 2 | $42 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Cordis US CORP. | 1 | $21 |
| Teleflex LLC | 1 | $21 |
| Terumo Medical Corporation | 1 | $19 |
| Boehringer Ingelheim | 1 | $16 |
| Ancora Heart, Inc. | 1 | $15 |
| Itamar Medical Inc | 1 | $14 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$4,943
- OPTIS$1,254
- (P88) IGT Devices FM$521
- COROFLOW$381
- ELCA$317
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$149
- Conformable TAG Thoracic Endoprosthesis$142
- LifeSPARC$132
- KENGREAL$124
- (6571) Eagle Eye$122
- CAMZYOS$114
- (6371) Laser CVX300$104
- CoreValve Evolut$104
- PRESSUREWIRE$101
- LifeVest$100
How this compares
$20,766 in reported general payments places this provider in the 95th percentile of 101 cardiovascular disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 79 | $102,243 |
| Repatha SureclickEvolocumab | 108 | $67,163 |
| BrilintaTicagrelor | 27 | $31,305 |
| JardianceEmpagliflozin | 28 | $26,791 |
| XareltoRivaroxaban | 24 | $24,696 |
| EntrestoSacubitril/Valsartan | 18 | $18,349 |
| OzempicSemaglutide | 12 | $11,350 |
| Praluent PenAlirocumab | 17 | $9,268 |
| Atorvastatin Calcium | 354 | $5,197 |
| Rosuvastatin Calcium | 214 | $4,632 |
| Metoprolol Succinate | 244 | $3,661 |
| ClopidogrelClopidogrel Bisulfate | 113 | $1,733 |
| Losartan Potassium | 178 | $1,708 |
| Ezetimibe | 36 | $1,638 |
| Lisinopril | 135 | $1,374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $57 | $102,24379 claims |
| AstraZenecaBrilinta | $83 | $31,30527 claims |
| Boehringer IngelheimJardiance | $16 | $26,79128 claims |
| Johnson & JohnsonXarelto | $112 | $24,69624 claims |
| NovartisEntresto | $365 | $18,34918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 cardiovascular disease providers in New Mexico.
Other cardiovascular disease in Albuquerque
- Abinash AchrekarAlbuquerque$88K
- Adam BanksAlbuquerque$38K
- Leonardo MaciasAlbuquerque$15K
- Carolina Ponce OrellanaAlbuquerque$12K
- Phillip CampAlbuquerque$11K
- Warren LaskeyAlbuquerque$10K
- Kayvan ElliniAlbuquerque$10K
- Bilal AlqamAlbuquerque$8K
- Daniel FriedmanAlbuquerque$6K
- Robert TaylorAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.